Girona, Spain

Iteng Ng Choi

This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Medichem, S.a.. Active years: 2021.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Iteng Ng Choi. Retrieved from https://idiyas.com/inventor/iteng-ng-choi

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

 

Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2021

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Iteng Ng Choi

Introduction

Iteng Ng Choi is a notable inventor based in Girona, Spain. He has made significant contributions to the field of pharmaceuticals, particularly through his innovative processes in drug synthesis. His work has led to advancements that benefit both the medical community and patients.

Latest Patents

Iteng Ng Choi holds a patent for a process related to the synthesis of a cyclodextrin derivative. This invention pertains to an improved method for synthesizing Sugammadex or its salts, achieving high purity levels. The patent also includes pharmaceutical compositions that utilize this high-purity Sugammadex, showcasing the practical applications of his work.

Career Highlights

Choi is currently employed at Medichem, S.A., a company known for its focus on pharmaceutical development. His role there has allowed him to apply his expertise in drug synthesis and contribute to the company's innovative projects.

Collaborations

Throughout his career, Iteng Ng Choi has collaborated with esteemed colleagues such as Jordi Puig Serrano and Jordi Bosch I Llado. These partnerships have fostered a collaborative environment that enhances the quality and impact of their research.

Conclusion

Iteng Ng Choi's contributions to pharmaceutical innovation, particularly through his patent on Sugammadex synthesis, highlight his role as a key figure in the industry. His work continues to influence the development of high-purity pharmaceutical products.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…